Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study) (GUARD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02246439
Recruitment Status : Completed
First Posted : September 22, 2014
Last Update Posted : February 12, 2018
Information provided by (Responsible Party):
RedHill Biopharma Limited

Brief Summary:

Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (BEKINDA) (Ondansetron 24 mg Bimodal Release Tablets) for Acute Gastroenteritis.

The study will evaluate the safety and efficacy of RHB-102 (BEKINDA) in treating Acute Gastroenteritis, by comparing it to placebo.

Condition or disease Intervention/treatment Phase
Gastroenteritis Gastritis Drug: RHB-102 Drug: Placebo Oral Tablet Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
Study Start Date : September 2014
Actual Primary Completion Date : February 13, 2017
Actual Study Completion Date : February 16, 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Ondansetron
U.S. FDA Resources

Arm Intervention/treatment
Experimental: RHB-102
RHB-102, Bimodal Release Ondasetron Tablets
Drug: RHB-102
RHB-102, Bimodal Release Ondasetron Tablets
Placebo Comparator: Placebo
Drug: Placebo Oral Tablet
Other Name: Placebo

Primary Outcome Measures :
  1. Proportion of patients without further vomiting, without rescue medication, and who were not given intravenous hydration from 30 minutes post first dose until 24 hours post dose [ Time Frame: Day 1 ]

Secondary Outcome Measures :
  1. Frequency of vomiting [ Time Frame: Release from ED through 4 days post first dose ]
  2. Proportion of patients receiving rescue antiemetic therapy [ Time Frame: Day 1 ]
  3. Proportion of patients receiving intravenous fluids [ Time Frame: Day 1 ]
  4. Proportion of patients requiring hospitalization [ Time Frame: Day 1 ]
  5. Proportion of patients returning to emergency department for gastrointestinal symptoms [ Time Frame: Day1-4 ]
  6. Severity of nausea, evaluated by Likert scales [ Time Frame: Day 1-4 ]
  7. Incidence and frequency of diarrhea [ Time Frame: Day 1-4 ]
  8. Adverse event profiles [ Time Frame: Day 1-4 ]
  9. Time to resumption of normal activities (work/school/household) [ Time Frame: Days 1-4 ]
  10. Time from first dose of study medication to discharge from ED, extended observation unit or hospital, whichever comes last [ Time Frame: Day 1 ]
  11. Time from first dose of study medication to first episode of vomiting [ Time Frame: Day 1 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 85 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have vomited at least twice in the 4 hours preceding signing informed consent. A vomiting episode is defined as an episode of forceful expulsion of stomach contents. Retching if a patient has already emptied his or her gastric contents is also considered vomiting episode. A distinct episode is characterized by a clear break in vomiting activity of at least 5 minutes
  • Emesis must have been nonbloody (streaks of blood presumed due to force of retching are allowed)
  • All patients (and a parent or guardian for patients <age 18) must sign informed consent.

Exclusion Criteria:

  • Severe dehydration. Severe dehydration is defined as two or more of the following criteria in the presence of decreased intake and increased output due to vomiting or diarrhea: Absent or severely decreased urine output; weak pulse and/or low blood pressure; parched mucous membranes; lethargy, confusion, delirium or loss of consciousness
  • Signs and symptoms severe enough to require immediate parenteral hydration and/or parenteral antiemetic medication
  • Temperature>39.0
  • Likely etiologies for acute vomiting and diarrhea other than acute infectious or toxic gastroenteritis or gastritis. This includes signs of an acute abdomen, which may require surgical intervention
  • Chemically-induced gastroenteritis, e.g., from alcohol, other drugs of abuse or other irritant chemicals
  • Use within 24 hours of study entry of specific medication for treatment of nausea and/or vomiting, e.g., 5-HT3 antagonists or phenothiazines, or receipt of any IV fluid for any reason. Nonspecific gastrointestinal remedies, such as antacids, proton pump inhibitors and homeopathic remedies, are permitted.
  • Congestive heart failure, bradyarrhythmia (baseline pulse<55/min), known long QT syndrome
  • Patient who have known QTc prolongation > 450 msec, noted on prior or screening ECG, or who are taking medication known to cause QT prolongation. Note: for current list of medications known to cause QT prolongation see: Use list showing drugs with known risk TdP.
  • Known underlying disease which could affect assessment of hydration or modify outcome of treatment, e.g., renal failure, diabetes mellitus, liver disease, alcoholism. Patients with type 2 diet-controlled diabetes mellitus whose baseline blood glucose is <200 may be entered into the study
  • Abdominal surgery within the past 3 months
  • History of bariatric surgery or bowel obstruction at any time
  • Hypersensitivity or other known intolerance to ondansetron or other 5-HT3 antagonists
  • Patient has taken apomorphine within 24 hours of screening
  • Patient has previously participated in this study
  • Patient has participated in another interventional clinical trial, for any indication, in the past 30 days
  • For women of childbearing potential: documented or possible pregnancy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02246439

  Show 26 Study Locations
Sponsors and Collaborators
RedHill Biopharma Limited
Principal Investigator: Robert Silverman, MD Long Island Jewish Hospital (LIJ)

Responsible Party: RedHill Biopharma Limited Identifier: NCT02246439     History of Changes
Other Study ID Numbers: RHB-102-01
First Posted: September 22, 2014    Key Record Dates
Last Update Posted: February 12, 2018
Last Verified: November 2016

Keywords provided by RedHill Biopharma Limited:

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Gastrointestinal Diseases
Digestive System Diseases
Stomach Diseases
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Dermatologic Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Anti-Anxiety Agents